Advanced search    

Search: authors:"Yuji Ishida"

10 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Quantitative analysis of the relationship between maxillary incisors and the incisive canal by cone-beam computed tomography in an adult Japanese population

Background In setting goals for orthodontic treatment, determining the morphologies of the alveolar bone and maxillary incisor root is important for avoiding root resorption, dehiscence, and fenestration. This study aimed to analyze the configurational relationships among maxillary incisors, the alveolar border, and the incisive canal by cone-beam computed tomography (CBCT). ...

Ultrasound microbubble-mediated transfection of NF-κB decoy oligodeoxynucleotide into gingival tissues inhibits periodontitis in rats in vivo

supported in part by Grants-in-Aid for Scientific Research (24792322) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (KAKENHI). Yuji Ishida, https://www. ... ) for English language editing. Conceptualization: Hiroyuki Yamaguchi, Yuji Ishida, Jun Hosomichi, Jun-ichi Suzuki, Sawa Data curation: Hiroyuki Yamaguchi, Yuji Ishida, Jun Hosomichi, Kasumi Hatano, Risa

Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

. Masataka Tsuge received research funding from Bristol-Meyers Squibb. Yuji Ishida and Chise Tateno are employed by PhoenixBio Co. Ltd. There are no patents, products in development or marketed products to

Enhanced p122RhoGAP/DLC-1 Expression Can Be a Cause of Coronary Spasm

Background We previously showed that phospholipase C (PLC)-δ1 activity was enhanced by 3-fold in patients with coronary spastic angina (CSA). We also reported that p122Rho GTPase-activating protein/deleted in liver cancer-1 (p122RhoGAP/DLC-1) protein, which was discovered as a PLC-δ1 stimulator, was upregulated in CSA patients. We tested the hypothesis that p122RhoGAP/DLC-1 ...

Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice

We have used homozygous albumin enhancer/promoter-driven urokinase-type plasminogen activator/severe combined immunodeficient (uPA/SCID) mice as hosts for chimeric mice with humanized livers. However, uPA/SCID mice show four disadvantages: the human hepatocytes (h-heps) replacement index in mouse liver is decreased due to deletion of uPA transgene by homologous recombination, ...

Isolation and Characterization of Highly Replicable Hepatitis C Virus Genotype 1a Strain HCV-RMT

: Masaaki Arai and Asako Takagi are employees of Mitsubishi Tanabe Pharma Corporation and Yuji Ishida and Chise Tateno are employees of PhoenixBio Co., Ltd. The other authors have no conflicts of interest to

Assessment of organ dose reduction and secondary cancer risk associated with the use of proton beam therapy and intensity modulated radiation therapy in treatment of neuroblastomas

Background To compare proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT) with conformal radiation therapy (CRT) in terms of their organ doses and ability to cause secondary cancer in normal organs. Methods Five patients (median age, 4 years; range, 2–11 years) who underwent PBT for retroperitoneal neuroblastoma were selected for treatment planning ...

Re-elevation of T-wave from day 2 to day 4 after successful percutaneous coronary intervention predicts chronic cardiac systolic dysfunction in patients with first anterior acute myocardial infarction

This study evaluates the clinical significance of re-elevation of T-wave in patients with ST segment elevation acute myocardial infarction (STEMI) undergoing successful percutaneous coronary intervention (PCI). Resolution of ST elevation within 24 h after reperfusion is associated with better outcome. However, little is known about the serial electrocardiography (ECG) changes and ...


DATA Hiroshi Fuji, Yuji Ishida, Tsuyoshi Onoe, Touru Kanda, Yuki Kase, Haruo Yamashita, Shigeyuki Murayama, and Yoko Nakasu; Shizuoka Cancer Center Hospital, Nagaizumi, Shizuoka-pref., Japan


CHEMOTHERAPY FOR A PATIENT WITH RECURRENT GERM CELL TUMOR Hiromi Kato, Hiroshi Fuji, Yoko Nakasu, Yuji Ishida, and Shoko Okawada; Shizuoka Cancer Center, Shizuoka, Japan INTRODUCTION: Standard treatment for